---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-240438"
form_type: "8-K"
ticker: "ORGO"
cik: "0001661181"
company_name: "Organogenesis Holdings Inc."
filed_at: "2021-08-09T23:59:59+00:00"
generated_at: "2026-06-29T18:54:20.036070+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Organogenesis Q2 revenue $123.2M (+79%), net income $20.7M; new $200M credit facility

## Summary
- Net revenue $123.2M (+79% YoY); Advanced Wound Care $111.4M (+87%), Surgical & Sports Med $11.8M (+27%).
- Net income $20.7M ($0.15 diluted EPS) vs loss $5.2M; adjusted EBITDA $25.1M (20.4% of revenue).
- FY2021 revenue guidance raised to $456-472M (35-40% growth); GAAP net income and adjusted EBITDA positive.
- New $200M credit facility ($75M term loan + $125M revolver) with LIBOR-based pricing; prior facility terminated.
- Legacy stockholders agreed not to sell shares until March 1, 2022 unless via underwritten secondary offering.

## SEC filing metadata
- accession: 0001193125-21-240438
- form_type: 8-K
- ticker: ORGO
- cik: 0001661181
- company_name: Organogenesis Holdings Inc.
- filed_at: 2021-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 2.02, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661181/000119312521240438/0001193125-21-240438-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661181/000119312521240438/d184440d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-240438
- JSON: https://secwatch.observer/filing/0001193125-21-240438.json
- Plain text: https://secwatch.observer/filing/0001193125-21-240438.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.